Nature Medicine：尼帕病毒mRNA疫苗，首次人体实验数据发布

Core Insights - Nipah virus (NiV) poses a significant public health threat due to its pandemic potential and the absence of approved vaccines or treatments [2] - The virus has a high mortality rate ranging from 40% to 75% in reported outbreaks, with evidence of human-to-human transmission [2] - The World Health Organization has prioritized the development of safe and effective vaccines against Nipah virus [2] Group 1: Nipah Virus Overview - Nipah virus was first identified in Malaysia in 1998, causing viral encephalitis among pig farmers [2] - Since then, sporadic outbreaks have occurred in Singapore, India, and the Philippines, with Bangladesh experiencing annual outbreaks since 2001 [2] - The natural reservoir for the virus is fruit bats, which have a wide distribution, increasing the risk of future outbreaks [2] Group 2: Vaccine Development - A phase 1 clinical trial for an mRNA vaccine (mRNA-1215) developed by Moderna was published, showing promising safety and immunogenicity results [3][4] - The trial involved 40 healthy adults receiving varying doses of the vaccine, with the primary endpoints focusing on safety and tolerability [6] - Common adverse events included mild injection site pain (82%) and mild discomfort (40%), with no serious adverse events reported [7] Group 3: Immunogenicity Results - The vaccine induced strong antibody responses against the Pre-F and glycoprotein G, with neutralizing antibody titers observed within two weeks of initial vaccination [7] - Booster doses enhanced the immune response, maintaining high antibody levels for at least one year post-vaccination [7] - These findings support the continued clinical development of mRNA-1215 as a candidate vaccine for high-risk populations during Nipah virus outbreaks [13]